PHK
LFCR icon

Point72 Hong Kong’s Lifecore Biomedical LFCR Stock Holding History

Point72 Hong Kong’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-855
Closed -$8K – 950
2022
Q3 		$8K Buy
855
+675
+375% +$6.86K ﹤0.01% 1752
2022
Q2 		$2K Buy
+180
New +$1.78K ﹤0.01% 1789
2021
Q3 		– Sell
-808
Closed -$9K – 2240
2021
Q2 		$9K Buy
+808
New +$9.31K ﹤0.01% 1750

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Point72 Hong Kong's LFCR Position: Q4 2022 in Review

Point72 Hong Kong sold out of Lifecore Biomedical (LFCR) in Q4 2022, closing a stake of 855 shares — an estimated $8K sold.

Point72 Hong Kong first reported a position in LFCR in Q2 2021 and held it in 3 quarters. The position peaked at $9K in Q2 2021. 93 funds tracked by Wall St. Rank hold LFCR as of Q4 2022.

  • Point72 Hong Kong reported no remaining Lifecore Biomedical position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 855 Lifecore Biomedical shares in Q4 2022, an estimated $8K.
  • Point72 Hong Kong first reported a position in Lifecore Biomedical in Q2 2021 and held it in 3 quarters.
  • Point72 Hong Kong's Lifecore Biomedical position peaked at $9K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.